Risks in new drug development: Approval success rates for investigational drugs

被引:298
|
作者
DiMasi, JA [1 ]
机构
[1] Tufts Univ, Tufts Ctr Study Drug Dev, Boston, MA 02111 USA
关键词
D O I
10.1067/mcp.2001.115446
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:297 / 307
页数:11
相关论文
共 50 条
  • [41] Investigational new drugs for brain cancer
    Staedtke, Verena
    Bai, Ren-Yuan
    Laterra, John
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (08) : 937 - 956
  • [43] REGULATORY ASPECTS OF INVESTIGATIONAL NEW DRUGS
    ARBIT, HM
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1978, 35 (01): : 81 - 84
  • [44] Approval of new drugs for glioblastoma
    Weller, Michael
    Stupp, Roger
    CURRENT OPINION IN NEUROLOGY, 2009, 22 (06) : 617 - 618
  • [45] Success and Futility Criteria for Accelerated Approval of Oncology Drugs
    Xi, Dong
    Gou, Jiangtao
    PHARMACEUTICAL STATISTICS, 2025, 24 (02)
  • [46] DRUG RESEARCH AND DEVELOPMENT OF NEW DRUGS
    不详
    JOURNAL OF SCIENTIFIC & INDUSTRIAL RESEARCH, 1962, A 21 (05): : 226 - &
  • [47] Investigational new drugs for the treatment of leishmaniasis
    Sundar, Shyam
    Singh, Vishal Kumar
    Agrawal, Neha
    Singh, Om Prakash
    Kumar, Rajiv
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (10) : 1029 - 1046
  • [48] SUCCESS RATES IN THE UNITED-STATES DRUG DEVELOPMENT SYSTEM
    SHECK, L
    COX, C
    DAVIS, HT
    TRIMBLE, AG
    WARDELL, WM
    HANSEN, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (05) : 574 - 583
  • [49] Optimizing Expedited Safety Reporting for Drugs and Biologics Subject to an Investigational New Drug Application
    Patrick Archdeacon
    Cheryl Grandinetti
    José M. Vega
    David Balderson
    Judith M. Kramer
    Therapeutic Innovation & Regulatory Science, 2014, 48 : 200 - 207
  • [50] NEW FDA DRUG APPROVAL POLICIES AND HIV VACCINE DEVELOPMENT
    MARINER, WK
    AMERICAN JOURNAL OF PUBLIC HEALTH, 1990, 80 (03) : 336 - 341